FDA Mevacor OTC Switch Answer: Signs Point To “Not Approvable”
This article was originally published in The Tan Sheet
Executive Summary
FDA appears to have issued a "not approvable" letter in response to J&J/Merck's application to switch the cholesterol-lowering drug Mevacor (lovastatin 20 mg) over the counter